Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10 years

Radiotherapy and Oncology

Volumn 96, Issue 1, 2010, Pages 34-37

  Munro, Nicholas P ^a   Al Qaisieh, Bashar ^a   Bownes, Peter ^a   Smith, Jonathan ^a   Carey, Brendan ^a   Bottomley, David ^a   Ash, Dan ^a   Henry, Ann M ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Brachytherapy; Gleason score 7; Prostate cancer; Survival

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DOSIMETRY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ORGAN SIZE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RADIATION DOSE; TREATMENT OUTCOME; UNITED KINGDOM;

AGED; BIOPSY, NEEDLE; BRACHYTHERAPY; COHORT STUDIES; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; IODINE RADIOISOTOPES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953956154     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2010.03.004     Document Type: Article

References (14)

1. Henry A.M., Al-Qaisieh B., Gould K., et al. Outcomes following Iodine-125 monotherapy for localized prostate cancer: the results of Leeds ten year single centre brachytherapy experience. Int J Radiat Oncol Biol Phys 76 (2010) 50-56
2. Merrick G.S., Galbreath R.W., Butler W.M., et al. Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer. Cancer 110 (2007) 289-296
3. Potters L., Purrazzella R., Brustein S., et al. The prognostic significance of Gleason Grade in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 56 (2003) 749-754
4. Burdick M.J., Reddy C.A., Ulchaker J., et al. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer. Int J Radiat Oncol Biol Phys 73 (2009) 1439-1445
5. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement. Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
6. Kuban D.A., Levy L.B., Potters L., et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 65 (2006) 1487-1489
7. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881
8. Zelefsky M.J., Kuban D.A., Levy L.B., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67 (2007) 327-333
9. Sylvester J.E., Grimm P.D., Blasko J.C., et al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 67 (2007) 57-64
10. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
11. Nobes J.P., Wells I.G., Khaksar S.J., Money-Kyrle J.F., Laing R.W., and Langley S.E. Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience. Prostate Cancer Prostatic Dis 12 (2009) 61-66
12. Chan T.Y., Partin A.W., Walsh P.C., and Epstein J.I. Prognostic significance of Gleason score 3 + 4 versus Gleason score 4 + 3 tumor at radical prostatectomy. Urology 56 (2000) 823-827
13. Ho A.Y., Burri R.J., Cesaretti J.A., Stone N.N., and Stock R.G. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 75 (2009) 16-22
14. Ash D., Al-Qaisieh B., Bottomley D., Carey B., and Joseph J. The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer. Radiother Oncol 79 (2006) 185-189